Skip to content

Upcoming Webinar: From Edit to Insight: Faster Drug Discovery with HiBiT-Enabled Screens

Home > Webinars > Current page

HiBiT Webinar

Generating biologically relevant cell models is often the slowest and most critical step in the drug discovery process. For targeted protein degradation (TPD) and other small-molecule programs, real-time quantification of endogenous protein levels can provide decisive insights; however, conventional antibody assays and overexpression systems can add weeks to timelines.

Join Promega and EditCo to discover a streamlined path from CRISPR edit to actionable data. You’ll see how a single 11-amino-acid HiBiT tag, precisely inserted by EditCo and verified by deep NGS, converts your protein of interest into a bright Nano-Glo® biosensor with >6-log linear dynamic range. Then learn how Promega’s ready-made assays and high- throughput screening services translate that signal into degrader potency curves and kinetic profiles—often within days of receiving your cells.

In this session, you’ll learn: 

  • HiBiT fundamentals: why a tag this small delivers such a big, quantitative signal.
  • Editing at speed: how EditCo ships HiBiT knock-in pools or clones—NGS-verified and assay-ready—in as little as 10 weeks.
  • Assay to insight: leveraging Promega’s platforms to profile degrader efficacy, kinetics, and selectivity.
  • Beyond TPD: extending the same models to pathway modulation, target validation, and ortholog studies across your discovery pipeline.

Cut months off discovery timelines and illuminate your next breakthrough—faster than ever. (Co-sponsored by Promega Corporation and EditCo Bio)

Speakers:

amanda

Amanda Nieman, Ph.D. 

Senior Research Scientist, Promega Corporation

Dr. Amanda Nieman is a Senior Research Scientist on the Tailored R&D Solutions team at Promega Corporation. She earned her Ph.D. in Biochemistry from the University of Wisconsin–Milwaukee, where she studied novel imidazodiazepines in models of asthmatic and neuropathic inflammation. At Promega, she develops custom assay and screening solutions to support drug discovery and translational research, including NanoBRET® Target Engagement and protein-protein interaction assays using NanoBRET® and NanoBiT® technologies, as well as applications using HiBiT technology for quantifying endogenous protein dynamics. 
 

travis

Travis Hardcastle

Director of Product Management, EditCo Bio

Travis Hardcastle brings a strong foundation in cellular and molecular biology, seamlessly transitioning from hands-on research to leadership in commercial strategy. His career spans diverse environments, from private equity-backed startups navigating IPOs to multinational corporations, where he has successfully managed portfolios across mergers and acquisitions. With extensive experience in product management, Travis has led both marketing- and e-commerce-driven product lines as well as customized, sales-driven service offerings. His passion lies in developing innovative, customer-centric solutions that integrate cutting-edge technology with deep market insights, driving growth and scientific advancement.

Fill out the form below to save your spot!

fontawesome-6.4.2--Arrow Down Long